RE:For Notable. From "Science" 9Dec 21The "new" model of oncoloytic virus therapy is one that ONCY has been demonstrating in the application of pelareorep and its ability to stimulate the innate and adaptive immune system with the effect of overcoming an otherwise immunosuppressive tumor microenvironment (TME) in advance of the addition of checkpoint inhibitor therapy
Independent studies have recently shown that sequential administration of a checkpoint inhibitor with oncolytic viruses is clinically more effective than administering both agents at the same time.
ONCY has demonstrated that through I.V. administration of pelareorep several days before adding a checkpoint inhibitor, pelareorep 'trains' the immune system and works to overcome an otherwise immunosuppressive tumor microenvironment thus preparing the way for the synergistic administration of checkpoint inhibitor therapy.
Mounting evidence is confirming this discovery as this Melcher paper in Science has affirmed.